Lipid nanoparticles for targeted delivery of anticancer therapeutics: Recent advances in development of siRNA and lipoprotein-mimicking nanocarriers

Adv Drug Deliv Rev. 2023 Dec:203:115136. doi: 10.1016/j.addr.2023.115136. Epub 2023 Nov 7.

Abstract

The limitations inherent in conventional cancer treatment methods have stimulated recent efforts towards the design of safe nanomedicines with high efficacy for combating cancer through various promising approaches. A plethora of nanoparticles has been introduced in the development of cancer nanomedicines. Among them, different lipid nanoparticles are attractive for use due to numerous advantages and unique opportunities, including biocompatibility and targeted drug delivery. However, a comprehensive understanding of nano-bio interactions is imperative to facilitate the translation of recent advancements in the development of cancer nanomedicines into clinical practice. In this contribution, we focus on lipoprotein-mimicking nanoparticles, which possess unique features and compositions facilitating drug transport through receptor binding mechanisms. Additionally, we describe potential applications of siRNA lipid nanoparticles in the future design of anticancer nanomedicines. Thus, this review highlights recent progress, challenges, and opportunities of lipid-based lipoprotein-mimicking nanoparticles and siRNA nanocarriers designed for the targeted delivery of anticancer therapeutic agents.

Keywords: Apolipoprotein; Biological fluid; Cancer therapy; Ligand; Lipid nanoparticle; Lipoprotein; Protein corona; Receptor; siRNA.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / chemistry
  • Drug Delivery Systems
  • Humans
  • Lipoproteins
  • Nanoparticles* / chemistry
  • Neoplasms* / drug therapy
  • RNA, Small Interfering / genetics

Substances

  • RNA, Small Interfering
  • Lipid Nanoparticles
  • Antineoplastic Agents
  • Lipoproteins